Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Shareholder vote
confidence 95%
filed 2026-06-26
EX-99.1
This press release discloses the voting results of the 2026 Annual General Meeting held on June 26, 2026, including the re-election of all five director nominees (Ron Sade, Alyazi Saeed Ahmad Alkhattal Almheiri, Erez Simha, Tariq Salem Ebraheem Alsaman Alnuaimi, and Keren Maimon) with support ranging from 61.80% to 69.33%, and ratification of Reliant CPA PC as independent auditor with 99.08% support. The disclosure includes detailed voting tallies and results tables, which is the hallmark of shareholder_vote_results classification. This is material because it reflects shareholder confidence in the board during a contested proxy campaign by RBCH Ltd./RockawayX, and the outcome affects investor assessment of governance and board composition.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-26
Item 7.01
This Item 7.01 Regulation FD disclosure presents a corporate presentation detailing Hyperscale Data's strategic expansion plans for its Michigan and Montana data center campuses, including planned buildout of up to 52 MW of critical IT load capacity, land acquisition of approximately 48.5 acres, and a new robotics facility with anticipated revenue streams. While the disclosure is forward-looking and subject to conditions not yet satisfied (e.g., securing additional power capacity, obtaining necessary approvals), the scale of the planned capital expenditures, facility expansion, and new business lines (robotics operations) would materially affect a reasonable investor's assessment of the company's growth strategy and capital allocation. This is an operational/strategic disclosure rather than a specific event type like M&A or debt issuance.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-26
EX-99.1
The press release announces the closing of a registered direct offering of 673,006 common shares at CAD$3.74 per share, raising approximately CAD$2.5 million, plus a concurrent private placement of unregistered warrants. This is a classic dilutive equity issuance that increases share count and raises capital. The unregistered warrant component (issued under Section 4(a)(2) and Regulation D) is particularly characteristic of dilutive private placements at smaller issuers.
View raw filing on EDGAR →
6-K
Going Concern
confidence 92%
filed 2026-06-26
Braskem disclosed that a Brazilian bankruptcy court has granted a precautionary injunctive relief (Tutela de Urgência Cautelar) under Law No. 11,101/2005 (Brazil's bankruptcy law), ordering a 60-day stay of enforcement actions by creditors and initiating a mediation proceeding. This is a material financial restructuring event that signals substantial doubt about the company's ability to meet its obligations and continue as a going concern. The disclosure explicitly references prior Material Facts from June 25, 2026 and September 26, 2025, indicating an ongoing financial distress situation.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-26
Item 7.01
GameStop disclosed forward-looking guidance for fiscal year 2026 Adjusted EBITDA in excess of $600 million, representing a 74% increase from prior-year Adjusted EBITDA of $345.4 million. While this is a forward-looking financial projection rather than a historical earnings release, it is material guidance that would affect investor assessment of the company's financial trajectory. The disclosure does not fit cleanly into "earnings_release" (which typically covers actual historical results) but represents a significant forward-looking financial statement that a reasonable investor would consider material to their investment decision.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-26
Item 5.02
Kevin D. Miller ceased serving as president and chief executive officer of Profile Bank on June 22, 2026, which rendered him ineligible to serve as a member director of the Federal Home Loan Bank of Boston effective immediately. The filing centers on his departure from the Bank's board and loss of director status, with specific detail on his committee memberships (Executive, Audit, Finance, and Governance/Government Relations). This is a material departure of a director and officer from a financial institution's governance structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-26
Item 5.07
This is a clear disclosure of shareholder vote results from the 2026 Annual Meeting of Stockholders held on June 25, 2026, filed under Item 5.07. The filing reports voting outcomes on three proposals: election of 11 board members, advisory approval of executive compensation, and ratification of KPMG LLP as independent auditor. All three proposals passed with substantial majorities, making this a material governance event that affects investor understanding of board composition and shareholder approval of compensation and audit arrangements.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-26
EX-99.1
This exhibit discloses the results of voting at Takeda's 150th Annual General Meeting of Shareholders held on June 24, 2026, including approval votes on five proposals: dividend appropriation, election of eight directors (non-audit committee), election of three audit committee directors, election of a substitute audit committee director, and director bonuses. The document provides detailed voting tallies (approval, against, abstention) and approval percentages for each proposal, meeting the definition of shareholder_vote_results under Item 5.07 equivalent disclosure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 72%
filed 2026-06-26
Item 8.01
Visa deposited $250 million into a litigation escrow account, triggering downward adjustments to conversion rates for class B-1, B-2, and B-3 common stock held by U.S. financial institutions. The filing explicitly states these conversion rate adjustments have "the same effect on earnings per share as repurchasing the Company's class A common stock," resulting in material dilution to the as-converted share counts (reduction of approximately 6,658 to 740,184 shares across the three classes). This is a dilutive capital event affecting shareholder equity and EPS, though the mechanism is conversion-rate adjustment rather than a traditional equity issuance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-26
Item 5.07
This is a clear disclosure of shareholder vote results from HealthEquity's 2026 Annual Meeting held on June 25, 2026. The filing reports voting outcomes on five proposals: election of ten directors, ratification of PricewaterhouseCoopers LLP as auditor, advisory vote on named executive officer compensation, approval of the 2026 Employee Stock Purchase Plan, and approval of the Amended and Restated 2024 Equity Incentive Plan. All proposals were approved by stockholders, with detailed vote tallies (for, against, abstain, broker non-votes) provided for each matter, which is the standard format for Item 5.07 disclosures.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-06-26
Item 8.01
The Company announced an extension of a subscription rights offering to purchase common stock at $6.90 per share, with the new expiration date of July 15, 2026. This is a dilutive equity issuance that allows existing and new shareholders to purchase shares, which is material to investors as it affects share count and ownership dilution. While the extension itself is administrative, the underlying rights offering represents a material capital-raising activity that would affect a reasonable investor's assessment of the registrant's financing strategy and equity structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-26
Item 5.07
This Item 5.07 filing discloses the results of Blue Dolphin's Annual Meeting of Stockholders held on June 25, 2026, including voting outcomes on four proposals: election of five directors, Say on Pay advisory vote, Say on Pay Frequency advisory vote, and ratification of UHY LLP as independent auditor. The detailed vote tallies for each proposal are provided, which is the core disclosure required under Item 5.07 for shareholder vote results.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-26
Item 7.01
Monopar announced new Phase 3 clinical trial analyses for ALXN1840 showing superior neurologic and global clinical benefit versus standard of care in Wilson disease patients, to be presented at the European Academy of Neurology Congress. This disclosure of positive clinical trial data supporting a planned NDA submission is a material operational/clinical milestone for a clinical-stage biopharmaceutical company, but does not fit the specific categories of earnings_release (no financial results), exec_appointment/departure, or ma_activity. The event is clearly operational in nature—a significant clinical development milestone—making operational_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-06-26
Item 1.01
Vaxart entered into Modification No. 7 to its BARDA funding agreement, establishing approximately $345 million in total available funding (down from $461 million) with $68 million in firm fixed price amounts and the remainder for cost reimbursement, plus an additional $29 million release for trial completion and analyses. This modification creates a material direct financial obligation and represents a binding commitment of government funding to support the company's Phase 2b COVID-19 vaccine trial.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-06-26
Item 1.01
H.B. Fuller announced a recommended cash offer to acquire Advanced Medical Solutions Group plc for £2.85 per share (£715 million enterprise value), with boards of both companies having reached agreement. The transaction includes approximately $3 billion in committed bridge financing, is expected to add ~$300 million in annual revenues with ~$55 million in run-rate synergies, and is subject to shareholder approval and regulatory clearance with expected close by year-end 2026.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-26
Item 5.07
This Item 5.07 disclosure reports the results of Hydrofarm's 2026 annual meeting of stockholders held on June 23, 2026, including voting outcomes on three matters: election of a Class III director (Richard Christopher Yetter), advisory approval of named executive officer compensation, and ratification of CBIZ CPAs P.C. as independent auditor. The filing presents vote tallies (FOR, AGAINST, WITHHELD, ABSTAIN, BROKER NON-VOTE) for each proposal, which is the standard format for shareholder vote results disclosures under Item 5.07.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-26
Item 5.02
Paul M. Manheim, a Board member and chair of the Audit Committee, has determined not to stand for re-election and will retire from the Board effective at the 2026 annual meeting. This is a clear executive departure—a director leaving his role. While the departure is orderly and not due to dispute, the loss of a long-tenured board member (since 2011/2015) who chaired the Audit Committee is material to investors' assessment of governance and oversight.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-26
Item 5.07
This Item 5.07 disclosure reports the results of Horizon Technology Finance's annual meeting of stockholders held on June 26, 2026, including voting outcomes for two proposals: election of two Class I directors (Kimberley A. O'Connor and Thomas J. Allison) and ratification of Grant Thornton LLP as independent auditor. The filing presents vote tallies (For, Against, Withheld, Broker Non-Votes) for each proposal, which is the core content of shareholder_vote_results.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 85%
filed 2026-06-26
Item 7.01
The Company's board declared a dividend in the form of contingent value rights (CVRs) to holders of common stock and participating warrants, with an expected distribution range of approximately $10.6 million to $14.2 million (or $0.85 to $1.14 per share). While the disclosure emphasizes uncertainty regarding timing and amounts due to factors including asset sale adjustments and reserve requirements, the core event is the declaration of a dividend distribution to shareholders, which is material to investors assessing capital returns and the company's financial position post-restructuring.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-26
Item 8.01
The disclosure announces a rights offering (subscription rights offering) that commenced June 8, 2026, allowing shareholders to purchase common stock at $6.90 per share. The filing announces that the transferable subscription rights will now trade on OTC Markets under ticker "LGLGR" beginning June 29, 2026, with an expiration date of July 15, 2026. This is a dilutive equity issuance that would materially affect shareholder ownership and is a capital-raising activity typical of the dilutive_issuance category.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-06-26
Item 1.01
The Company entered into a $500,000 revolving line of credit (Reserve Line of Credit) with Bank Midwest on June 22, 2026, creating a new direct financial obligation. The facility is being used to finance equipment deposits for the Agricultural Products Segment, with the balance expected to convert to 15-year term debt at approximately 6.50% per annum. This is a material debt issuance that expands the Company's borrowing capacity and financial obligations.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-26
Item 3.01
Nasdaq notified Upexi on June 24, 2026, that the Company is not in compliance with Nasdaq Listing Rule 5635(a) due to two convertible note issuances totaling approximately $187 million that were convertible into 20% or more of pre-transaction shares without required shareholder approval. The Company has 45 days to submit a compliance plan or face potential delisting proceedings.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-26
Item 8.01
Upexi announced its addition to the Russell Microcap® Index effective June 29, 2026, a corporate milestone that increases visibility among institutional investors and index funds benchmarked to Russell indexes and broadens the Company's visibility within the institutional investment community.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-06-26
EX-99.1
Orion Digital received a Nasdaq notification on June 25, 2026, that its common shares have closed below the minimum US$1.00 per share requirement for continued listing under Nasdaq Listing Rule 5550(a)(2). The company has been given 180 calendar days (until December 22, 2026) to regain compliance. This is a classic delisting-risk disclosure: the registrant has failed to satisfy a continued listing rule and faces potential delisting if it does not remedy the deficiency within the specified compliance period.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-26
Item 5.07 discloses that stockholders approved a 1-for-10 reverse stock split by written consent on June 18, 2026, with 11,012,377 shares (approximately 60.97% of voting power) in favor. This is a shareholder vote result on a material corporate action that affects the capital structure and trading characteristics of the company's common stock.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-26
EX-99.1
PowerBank announces award of a $2.95 million USD federal contract with the US Department of Defense and Department of the Army for a covered parking canopy solar project with EV charging stations at the Armed Forces Reserve Center Farmingdale in New York. This is the company's first federal government project and represents a material operational milestone demonstrating entry into the federal procurement market, though it does not fit the specific categories of M&A activity, material litigation, or other named event types. The contract award is a significant business development event for a renewable energy company.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 75%
filed 2026-06-26
The Company entered into a Debt Conversion Agreement on June 22, 2026, whereby it will issue 10,000,000 Class B ordinary shares to CEO Houqi Zhang in settlement of a $7,000,000 interest-free loan. This is a dilutive equity issuance in exchange for debt forgiveness. While the shares are subject to a three-year lock-up, the issuance itself represents a material capital event that dilutes existing shareholders and should be disclosed as a material transaction affecting the equity structure.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-06-26
HCW Biologics disclosed a 1-for-6 reverse stock split effectuated in direct response to a Nasdaq Hearings Panel decision letter (May 29, 2026) that threatened "automatic delisting" if the company failed to maintain compliance with the Bid Price Rule (minimum $1.00 per share) prior to September 22, 2026. The filing explicitly states the reverse split was "intended to ensure compliance with the Bid Price Rule as well as other conditions required by the Panel" to avoid immediate delisting. This is a material disclosure of delisting risk and the company's remedial action to address it.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-26
The 8-K discloses fiscal year 2026 financial results for PCS Edventures! through an earnings press release dated June 26, 2026 (Exhibit 99). The release reports revenue of $6.3 million (down 14.4%), net income before tax of $321,455 (down 74.6%), and cash on hand of $2.7 million with no debt. This is a standard earnings release disclosure under Item 7.01 (Regulation FD Disclosure) with the press release furnished as Exhibit 99.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-26
The filing discloses the appointment of Stephen Hood, the Company's Chief Executive Officer and President, to the Board of Directors as a Class II director effective immediately. This is a clear executive appointment under Item 5.02, where the principal disclosed action is a person taking on a board role. The appointment is material as it represents a change in corporate governance and board composition.
View raw filing on EDGAR →
6-K
Legal Other
confidence 85%
filed 2026-06-26
The 6-K discloses a court order in a precautionary proceeding initiated by minority shareholders challenging two shareholder resolutions. The Court denied suspension of the May 2024 multiple voting rights resolution but granted suspension of the October 29, 2025 corporate purpose amendment pending further proceedings, citing concerns about overly broad language referencing the Italian "Golden Power" regime. The Company has filed an appeal scheduled for July 9, 2026. This is a material legal/regulatory event affecting corporate governance and the Company's operational scope, but does not fit the specific categories of material_litigation (no lawsuit against the Company), governance_other (the event is clearly legal/regulatory in nature), or other named types.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-26
The filing discloses Item 5.07 results from VirTra's June 23, 2026 annual meeting of stockholders, including election of five directors (John F. Givens II, Gregg C.E. Johnson, Michael T. Ayers, Lt. Gen. Maria R. Gervais, and Grant A. Barber), ratification of Haynie as independent auditors, approval of named executive officer compensation, and stockholder preference for annual advisory votes on executive compensation. These are standard shareholder vote results that materially affect governance and board composition.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-06-26
EX-99.1
The exhibit discloses biographies of three "Newly Appointed Directors" to KNOREX LTD: Kai Zhong (corporate lawyer), Lu Liu (accounting/taxation expert), and Truong Vinh Phu Le (VP of Operations and founding member). The document explicitly identifies these individuals as newly appointed directors, which constitutes an executive appointment event. Director appointments are material to investors as they affect board composition and governance.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-06-26
The filing discloses unaudited condensed interim consolidated financial statements and MD&A for BriaPro Therapeutics Corp. (a subsidiary of BriaCell) for the nine-month period ended April 30, 2026, filed under Item 7.01 (Regulation FD Disclosure). The financial statements reveal a pre-clinical biotech company with accumulated losses of $1.89M, a shareholders' deficit of $989.7K, and explicit going-concern language noting "material uncertainty" about the company's ability to continue operations. While the statements are unaudited and filed under Item 7.01 (not Item 2.02), the disclosure of interim financial results with going-concern doubt is material to investors. This is classified as financial_other rather than going_concern because the primary event is the disclosure of interim financial statements; the going-concern language is embedded within the statements rather than being the standalone focus of the 8-K.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-06-26
EX-99.1
This exhibit announces the filing and mailing of a management information circular for a special shareholder meeting to approve a proposed plan of arrangement between Uranium Royalty Corp. and Sweetwater Investors (Orion Resource Partners and Ontario Teachers' Pension Plan subsidiary). The transaction involves the Sweetwater Investors contributing approximately 92% interest in trona royalty assets and landholdings for aggregate consideration of approximately US$1.14 billion in cash and shares, resulting in a combination under a newly formed parent company (New URC). This constitutes a material acquisition/change of control transaction requiring shareholder approval.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-06-26
The filing discloses financial results for the fiscal year and quarter ended March 31, 2026, with a press release (Exhibit 99.1) announcing revenue of $7.7 million (107% YoY growth) and providing forward guidance. Item 2.02 explicitly states the Company "issued a press release announcing financial results for its fiscal quarter and year ended March 31, 2026." While the filing also includes a fiscal year-end change (Item 5.03), the primary disclosed event is the earnings announcement with material revenue growth and guidance.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-26
Item 5.02
Sandra Gurrola, Senior Vice President of Finance, delivered her notice of resignation effective July 3, 2026. The disclosure centers on her departure from the Company, which is material to investors as the CFO-level finance executive is a key officer. The resignation was not due to disagreement, and transition assistance is being arranged, but the principal event disclosed is the departure itself.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-06-26
ChronoScale Corporation entered into an unsecured Demand Grid Promissory Note with Applied Digital Corporation on June 26, 2026, establishing a line of credit with a maximum principal amount of $100,000,000. This is disclosed under Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of Direct Financial Obligation), creating a new direct financial obligation. The materiality is evident from the substantial credit facility amount and the related-party nature of the transaction involving significant shareholders and board overlap.
View raw filing on EDGAR →
6-K
Auditor Change
confidence 95%
filed 2026-06-26
The 6-K discloses the resignation of HTL International as the Company's independent registered public accounting firm effective immediately on June 22, 2026, and the subsequent appointment of Guangdong Prouden CPAs as the new auditor on June 25, 2026. This is a clear auditor change event. The filing explicitly states HTL International will not complete the audit for the fiscal year ended March 31, 2026, and includes the required Item 16F disclosures regarding disagreements and reportable events, with an auditor letter attached as Exhibit 16.1.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-26
The filing discloses a convertible promissory note issuance ($809,705.75 principal) that will automatically convert into common stock upon the pending Gravitics merger closing, with conversion shares subject to a 4.99% beneficial ownership limitation. While Item 1.01 frames this as a "material definitive agreement" and Item 2.03 addresses the debt obligation, the core material event is the dilutive equity issuance—the note's mandatory conversion into shares at $0.01966 per share represents a significant dilution to existing shareholders, particularly given the company's small size and the conversion mechanics tied to the merger.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-06-26
NextBoat Inc. entered into a Master Loan Agreement with RLLT Capital, LLC on June 22, 2026, creating a direct financial obligation. The Lender funded an initial loan of $2.0 million at 15.0% per annum interest, with additional fees (1% origination, 5% profit participation) and extension options. This is disclosed under Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of a Direct Financial Obligation), clearly constituting a debt issuance. The related-party nature (involving President Jason Ruegg's personal guarantee and stock pledge) and the high interest rate underscore materiality to investors.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 72%
filed 2026-06-26
CareCloud entered into a First Amendment to its Credit Agreement with Citizens Bank on June 25, 2026, modifying key terms of the underlying credit facility dated April 13, 2026. While the amendment itself is primarily administrative (extending pledge documentation deadlines, modifying acquisition conditions), it represents a material modification to the company's direct financial obligations and credit arrangements. The amendment's focus on post-closing obligations and liquidity conditions suggests this relates to a recently-closed credit facility, making it a material capital event.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-06-26
Applied Digital entered into an Incremental Assumption Agreement on June 26, 2026, increasing the aggregate principal amount of revolving credit commitments to $430 million under a Credit Agreement dated May 29, 2026. The filing explicitly states this increase "caused the Credit Agreement to become material to the Company and thereby requires disclosure under this Current Report on Form 8-K." Item 2.03 incorporates the credit facility information, confirming this is a creation of a direct financial obligation. While the filing also discloses a preferred equity purchase agreement amendment (Item 3.02), the primary material event is the substantial debt facility expansion.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 72%
filed 2026-06-26
Item 8.01
The filing discloses an amended and restated Senior Secured Convertible Promissory Note dated June 22, 2026, along with a Second Amendment to the Registration Rights Agreement with Leviston Resources, LLC. The concurrent deregistration of 950,000 shares of Class A Common Stock from the equity line of credit suggests a modification to an existing debt facility. This constitutes a material amendment to a direct financial obligation, fitting the debt_issuance category (which includes amendments to credit facilities and term loans).
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-26
Item 1.01
The filing discloses a private placement of 1,470,588 unregistered ADSs (or prefunded warrants) representing 80,000 ordinary shares per ADS, together with Series H, I, and J warrants. This is a classic dilutive equity issuance to raise capital. The amendment consolidates the second and third closing dates into a single combined closing on June 26, 2026, with the remaining 980,395 ADSs delivered on that date. The unregistered nature and warrant components are hallmarks of a dilutive capital raise at a small-cap biotech company.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-26
The filing discloses that Matinas BioPharma received notice on June 24, 2026 from NYSE American of non-compliance with continued listing standards under Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide, citing stockholders' equity of $3.02 million (below the $4.0 million minimum) and losses in five consecutive fiscal years. While the company's plan to regain compliance was accepted with a deadline of October 2, 2027, the filing explicitly warns that "if the Company does not regain compliance...then NYSE American staff may initiate delisting proceedings as appropriate." This is a material delisting risk event that would significantly affect investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-26
TEN Holdings announced a registered direct offering of 7.5 million shares of common stock at $1.00 per share, generating approximately $7.5 million in gross proceeds. Item 1.01 discloses entry into a Placement Agency Agreement with WestPark Capital, Inc. as the exclusive placement agent. This is a registered equity issuance that will dilute existing shareholders and is material to investors assessing the company's capital structure and ownership stakes.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 95%
filed 2026-06-26
The filing discloses under Item 4.01 that the Audit Committee dismissed BCRG as the independent registered public accounting firm and appointed Simon & Edward LLP (S&E) as the new auditor, effective June 24, 2026, following S&E's acquisition of BCRG's attest business. The filing confirms no disagreements or reportable events occurred with the prior auditor, and no pre-engagement consultations with S&E took place on accounting or auditing matters.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-26
Item 5.07
This Item 5.07 disclosure reports the results of a Special Meeting of Shareholders held on June 25, 2026, where shareholders voted on three proposals: approval of a merger agreement with Columbia Financial, Inc. (the principal matter), advisory approval of merger-related executive compensation, and adjournment authority. The merger proposal received overwhelming approval (27.7M votes for vs. 335K against), making this a material shareholder vote result on a transformative M&A transaction.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-06-26
Item 1.01
Bristow Group entered into a definitive Agreement and Plan of Merger to acquire Berry Aviation for $105 million in an all-cash transaction, expected to close in Q3 2026. The acquisition is expected to provide revenue diversification, earnings accretion, and expand government services capabilities.
View raw filing on EDGAR →